Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eton Pharmaceuticals, Inc. - Common Stock (NQ:ETON)

18.62 +0.08 (+0.43%)
Streaming Delayed Price Updated: 2:52 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eton Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
From Eton Pharmaceuticals
Via GlobeNewswire
Eton (ETON) Q2 Revenue Jumps 108%
Via The Motley Fool
Topics Intellectual Property
Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
Earnings Scheduled For August 7, 2025
 
Via Benzinga
A Look Ahead: Eton Pharmaceuticals's Earnings Forecast
 
Via Benzinga
The Analyst Verdict: Eton Pharmaceuticals In The Eyes Of 5 Experts
 
Via Benzinga
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes
From Eton Pharmaceuticals
Via GlobeNewswire
FDA Approves Eton Pharma's Oral Drug For Adrenal Insufficiency In Pediatric Patients, Analyst Sees Boost In 2025 Revenue
Eton Pharma's Khindivi has won FDA approval as a pediatric adrenal insufficiency treatment. It is projected to surge in sales and launch in the U.S. in June 2025. 
Via Benzinga
Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral Solution
From Eton Pharmaceuticals
Via GlobeNewswire
A Glimpse Into The Expert Outlook On Eton Pharmaceuticals Through 4 Analysts
 
Via Benzinga
Eton Pharmaceuticals Reports First Quarter 2025 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)
From Eton Pharmaceuticals
Via GlobeNewswire
Earnings Scheduled For May 13, 2025
 
Via Benzinga
Evaluating ETON PHARMACEUTICALS INC (NASDAQ:ETON) using Mark Minervini’s winning stock formula
A fundamental and technical analysis of (NASDAQ:ETON): Is ETON PHARMACEUTICALS INC (NASDAQ:ETON) suited for high growth investing? 
Via Chartmill
Eton Pharmaceuticals Out-Licenses International Rights to Increlex®
Esteve Pharmaceuticals, S.A. will commercialize Increlex in all markets outside the U.S. 
From Eton Pharmaceuticals
Via GlobeNewswire
5 Analysts Assess Eton Pharmaceuticals: What You Need To Know
 
Via Benzinga
Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
Earnings Scheduled For March 18, 2025
 
Via Benzinga
Eton Pharma Plans FDA Filing For ET-600 Oral Desmopressin Next Month, Eyes 2026 Launch
Eton Pharmaceuticals' ET-600 met bioequivalence standards in a study, with an FDA filing planned for April 2025 and a potential launch in early 2026. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600
From Eton Pharmaceuticals
Via GlobeNewswire
Rocket Companies, Novo Nordisk And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)
From Eton Pharmaceuticals
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.